ZymoGenetics files lawsuit against Bristol-Myers Squibb

	Tweet

ZymoGenetic has announced that it has filed a lawsuit against Bristol-Myers Squibb for infringement of its patents related to fusion protein technology. In the lawsuit filed with the United States District Court for the district of Delaware, ZymoGenetics is seeking injunctive relief and damages.

“We have a number of patents on fusion protein technology, which we believe are being infringed by Bristol-Myers Squibb,” said Bruce L.A. Carter Ph.D., President and Chief Executive Officer of ZymoGenetics. “It is important that ZymoGenetics protect its intellectual property rights for technology that it expended significant resources in developing, and we will enforce our patents through litigation when necessary.”

Amgen and Regeneron have previously licensed the use of the company’s patented fusion protein technology.

Further details about the lawsuit were not provided.

About Ig-fusion protein technology

Immunoglobulin fusion proteins are proteins that are produced using recombinant DNA technology whereby a portion of an antibody (e.g., heavy chain constant domain) is combined with the portion of a second protein (typically the portion of a cell-surface receptor that is responsible for binding to a growth factor).

http://www.zymogenetics.com/

RELATED STORIES:
Alfuzosin safe for older patients with cardiovascular disease   Substandard drugs threat to heart patients - study   Vioxx Heart Risk Finding Re-Ignites Debate   UMD Team Gives Drug Dropouts a Second Chance   Canada suspends attention deficit drug Adderall XR   Australia’s medicines regulator close to decision on herceptin   US FDA clears Barr’s generic version of Allegra   UK to save on generic medicines bill   Vaccine for Stomach Flu May be Possible   Medical journal says Merck deleted Vioxx dangers   GSK tests intravenous flu drug vs Roche’s Tamiflu   Ortho-McNeil to lower the price of contraceptive pills and patches

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]